Comparative Activity of Telithromycin Against Macrolide-Resistant Isolates of Streptococcus pneumoniae: Results of Two Years of the PROTEKT Surveillance Study

REFERENCES

• Hyde TB, Gay K, Stephens DS et al Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286 (15): 1857–62.
   Google Scholar
• Cizman M, Pokorn M, Seme K, Orazem A, Paragi M. The relationship between trends in macrolide use and resis-tance to macrolides of common respiratory pathogens. J Antimicrob Chemother 2001; 47: 475–7.
   PubMed Web of Science ®Google Scholar
• Pihlajamaki M, Kotilainen P, Kaurila T et al Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis 2001; 33: 483–8.
   Google Scholar
• Lynch III JP, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community acquired pneumonia. Clin Infect Dis 2002; 34 Suppl 1: S27–46.
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Doern CV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY antimicrobial surveil-lance program, 1997-1999. Clin Infect Dis 2001; 32 (Suppl.): S81–S93.
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ. Practice guidelines for the management of com-munity-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31 (2): 347–82.
   PubMed Web of Science ®Google Scholar
• Niederman MS, Mandell LA, Anzueto A et al American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163 (7): 1730–54.
   Google Scholar
• ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Society. Eur Respir J 1998; 11 (4): 986–91.
   Google Scholar
• Celli BR, Snider GL, Heffner J et al ATS statement: standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77–120.
   Google Scholar
• Siafakis NM, Vermeire P, Prode NB et al ERS consensus statement: optimal assessment and management of chron-ic obstructive pulmonary disease (COPD). Eur Respir J 1995; 9: 1398–420.
   Web of Science ®Google Scholar
• Ball P. Epidemiology and treatment of chronic bronchitis. Chest 1995; 108 (Suppl): 43S–52.
   Google Scholar
• Semchenko A, Baroody F, Culpepper L. Management of Acute Sinusitis and Acute Otitis Media. American Family Physician Monograph No. 1. Leawood, KS: American Academy of Family Physicians. 2001.
   Google Scholar
• Felmingham D, Grtineberg RN and the Alexander Project Group. The Alexander Project 1996-1997: latest sus-ceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191–203.
   Google Scholar
• Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991; 35: 1267–72.
   PubMed Web of Science ®Google Scholar
• Sutcliffe J. Resistance to macrolides mediated by efflux mechanisms. Curr Opin Investig Drugs 1999; 1: 403–12.
   Google Scholar
• Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996; 40: 1817–24.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Douthwaite S, Morrissey I et al Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999/2000 study. Antimicrob Agents Chemother 2003; 47, 1777–83.
   PubMed Web of Science ®Google Scholar
• Tait-Kamradt A, Davies T, Appelbaum PC et al Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44: 3395–401.
   PubMed Web of Science ®Google Scholar
• Canu A, Malbruny B, Coquemont M, Davies TA, Appelbaum PC, Leclerq R. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, strep-togramin, and telithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46: 125–31.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Morrissey I, Bakker S, Felmingham D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyo-genes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002; 50 (Suppl. 51): 39–47.
   PubMed Web of Science ®Google Scholar
• Shortridge VD, Doern GV, Brueggemann AB, Beyer JM, Flamm RK. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicen-tre antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 1999; 29: 1186–8.
   PubMed Web of Science ®Google Scholar
• Barry AL, Fuchs PC, Brown SD. In vitro activities of the ketolide HMR3647 against recent Gram-positive clinical isolates and Haemophilus influenzae. Antimicrob Agents Chemother 1998; 42: 2138–40.
   PubMed Web of Science ®Google Scholar
• Bonnefoy A, Girard AM, Agouridas C, Chantot JF. Ketolides lack inducibility properties of MLS(B) resistance phe-notype. J Antimicrob Chemother 1997; 40: 85–90.
   PubMed Web of Science ®Google Scholar
• Hansen LH, Mauvais P, Douthwaite S. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 1999; 31: 623–32.
   PubMed Web of Science ®Google Scholar
• Grtineberg RN, Felmingham D, and the Alexander Project Group. Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of commu-nity-acquired, lower respiratory tract bacterial pathogens. Diag Microbiol Infect Dis 1996; 25: 169–81.
   Google Scholar
• Sahm DF, Jones ME, Hickey ML, Diakun DR, Mani SV, Thornsberry C. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. J Antimicrob Chemother 2000; 45: 457–66.
   PubMed Web of Science ®Google Scholar
• Felmingham D. The need for antimicrobial resistance surveillance. J Antimicrob Chemother 2002; 50 (Suppl. 51): 1–7.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; twelfth informational supplement. NCCLS document M 100-S12. NCCLS, Wayne, PA, 19087, 2002.
   Google Scholar
• Farrell DJ, Morrissey I, Bakker S, Felmingham D. Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid-cycle PCR with microwell-format probe hybridisation. J Antimicrob Chemother 2001; 48: 541–4.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Morrissey I, Bakker S, Buckridge S, Borger J, Felmingham D. Association between ribosomal mutations, macrolide resitance (MACR) and reduced susceptibility to line-zolid or quinupristin/dalfopristin (Q/D) in S. pneumoniae (SPN). In Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2003. Abstract C2-69, p. 112. American Society for Microbiology, Washington, DC, USA.
   Google Scholar
• Gay K, Baughman W, Miller Y et al The emergence of Streptococcus pneumoniae resistant to macrolide antimicro-bial agent: a 6-year population-based assessment. J Infect Dis 2000; 182: 1417–24.
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial surveil-lance program, 1997-1999. Clin Infect Dis 2001; 32 (Suppl 2): S81–93.
   PubMed Web of Science ®Google Scholar
• Marchese A, Schito GC. Resistance patterns of lower respiratory tract pathogens in Europe. Int J Antimicrob Agents 2000; 16 (Suppl 1): S25–9.
   PubMed Web of Science ®Google Scholar
• Richard MP, Aguado AG, Mattina R, Marre R. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance. J Antimicrob Chemother 1998; 41 (2): 207–14.
   Google Scholar
• Verhaegen J, Verbist L. In vitro activity of the new ketolide telithromycin and other antibiotics against Streptococcus pneumoniae in Belgium. Acta Clin Belg 2001; 56 (6): 349–53.
   PubMed Web of Science ®Google Scholar
• Kim SN, Kim SW, Choi IH, Rhee DK. High incidence of multidrug-resistant Streptococcus pneumoniae in South Korea. Microb Drug Res 1996; 2 (4): 401–6
   PubMed Web of Science ®Google Scholar
• Song J-H, Lee NY, Ichiyama S et al Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Clin Infect Dis 1999; 28: 1206–11.
   PubMed Web of Science ®Google Scholar
• Ip M, Lyon DJ, Yung RW, Chan C, Cheng AF. Macrolide resistance in Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 2001; 45 (5): 1578–80.
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J et al Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343: 1917–24.
   PubMed Web of Science ®Google Scholar
• Marchese A, Tonoli E, Debbia EA, Schito GC. Macrolide resistance mechanisms and expression of pheno-types among Streptococcus pneumoniae circulating in Italy. J Antimicrob Chemother 1999; 44: 461–4.
   PubMed Web of Science ®Google Scholar
• Tait-Kamradt A, Davies T, Cronan M, Jacobs MR, Appelbaum PC, Sutcliffe J. Mutations in 23S rRNA and ribo-somal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000; 44, 2118-25.
   Google Scholar